Denzler B, Reubi J C
Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Switzerland.
Cancer. 1999 Jan 1;85(1):188-98. doi: 10.1002/(sici)1097-0142(19990101)85:1<188::aid-cncr26>3.0.co;2-3.
The vascular system of the tumor bed plays an important function in tumor growth regulation. Recent studies have suggested that the vasoactive peptides somatostatin and substance P may have a potential role in the tumor bed of selected tumors.
In the current study, somatostatin receptors were evaluated with in vitro receptor autoradiography using 125I-[Tyr3]-octreotide in the peritumoral vessels of a large group of 215 primary human tumors and 25 metastases of various tumor origin, with particular emphasis on receptor incidence, distribution, homogeneity, and density.
High affinity somatostatin receptors were found in the peritumoral veins of 22 of 22 gastric carcinomas, 25 of 39 breast carcinomas, 15 of 20 renal cell carcinomas, 14 of 27 prostate carcinomas, 4 of 10 endometrial carcinomas, 4 of 11 pancreatic adenocarcinomas, 4 of 13 nonsmall cell lung carcinomas, as well as in 3 of 4 parathyroid adenomas, 3 of 3 medullary thyroid carcinomas, 3 of 23 gastroenteropancreatic tumors, 14 of 25 soft tissue tumors, 3 of 5 melanomas but in none (0 of 13) of the ovarian carcinomas studied. In addition, somatostatin receptors were identified in veins surrounding lymph node, bone, and lung metastases of various tumor types. In all investigated tissues, receptors could not be identified in arteries. There was a considerable variability in the relative number of veins expressing somatostatin receptors and in the receptor density levels. Evidence of an overexpression of somatostatin receptors could be established in the peritumoral veins of gastric carcinoma when compared with the receptor expression in normal gastric vessels.
The expression of somatostatin receptors in peritumoral veins appears to be a general, tumor-related, but highly variable phenomenon. Although their pathophysiologic role is unclear, these receptors may be considered as novel targets for cancer diagnosis and therapy with somatostatin analogs.
肿瘤床的血管系统在肿瘤生长调节中发挥着重要作用。最近的研究表明,血管活性肽生长抑素和P物质可能在某些特定肿瘤的肿瘤床中发挥潜在作用。
在本研究中,使用125I-[酪氨酸3]-奥曲肽通过体外受体放射自显影技术,对215例原发性人类肿瘤和25例不同肿瘤来源的转移瘤的瘤周血管中的生长抑素受体进行评估,特别关注受体的发生率、分布、同质性和密度。
在22例胃癌中的22例、39例乳腺癌中的25例、20例肾细胞癌中的15例、27例前列腺癌中的14例、10例子宫内膜癌中的4例、11例胰腺腺癌中的4例、13例非小细胞肺癌中的4例,以及4例甲状旁腺腺瘤中的3例、3例甲状腺髓样癌中的3例、23例胃肠胰腺肿瘤中的3例、25例软组织肿瘤中的14例、5例黑色素瘤中的3例中,瘤周静脉发现了高亲和力生长抑素受体,但在所研究的13例卵巢癌中均未发现(0例)。此外,在各种肿瘤类型的淋巴结、骨和肺转移灶周围的静脉中也鉴定出了生长抑素受体。在所有研究的组织中,动脉中未发现受体。表达生长抑素受体的静脉相对数量和受体密度水平存在相当大的差异。与正常胃血管中的受体表达相比,胃癌瘤周静脉中可证实生长抑素受体的过表达。
瘤周静脉中生长抑素受体的表达似乎是一种普遍的、与肿瘤相关但高度可变的现象。尽管其病理生理作用尚不清楚,但这些受体可被视为使用生长抑素类似物进行癌症诊断和治疗的新靶点。